The REACH study found that 97% of women and girls in Uganda, South Africa and Zimbabwe are happy to work with HIV prevention methods - globally, half of all people living with HIV are women.
The team will have results to discuss in April, 2022 - they nurse the hope that this HIV vaccine could stop different geographical strains, after 40 years of no cure.
A study released yesterday (28 June) found that it would be safe to mix Pfizer and AstraZeneca doses, which could speed up UK vaccine roll-out if adopted.
The World Health Organisation on Friday (18 June) said that the Delta variant, originating in India, would be globally dominant due to "significantly increased transmissibility".
Professor Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, explores how the MDR will impact clinical trials.
Dr Mathias Allemand and Dr Patrick L. Hill discuss the complex factors contributing to healthy ageing, and explore the ways in which personality traits can be considered as a component.
The German-made CureVac vaccine has given a result of 47% efficacy, much lower than expected - now, the proposed delivery of 225 million doses to the EU is at risk.
A new study found that the Novavax vaccine was 93.2% effective against the Alpha variant - with no clarification about vaccine performance against the Delta variant.
Over the last three months, scientists have been tracing rare instances of blood clots in veins in connection to the AstraZeneca COVID vaccine - now, they have the first evidence of arterial blood clots, which can cause stroke.
